| 2025/0114,387 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN FOR PREVENTING OR TREATING OBESITY IN CANINE ANIMALS | Jan 20, 23 | Apr 10, 25 | Not available |
| 2025/0114,419 | INTESTINAL HEALTH PROMOTING COMPOSITIONS | Aug 12, 24 | Apr 10, 25 | Not available |
| 2025/0114,422 | COMPOSITION FOR LIPOLYSIS COMPRISING EXTRACT OF MORUS ALBA L. BARK AND MAGNOLIA OFFICINALIS BARK AS ACTIVE INGREDIENT | Feb 09, 23 | Apr 10, 25 | BOINBIO-CONVERGENCE CO., LTD. |
| 2025/0114,426 | USE OF COLLAGEN HYDROLYSATE IN PREVENTION AND/OR TREATMENT OF FOOD CRAVING | Feb 01, 23 | Apr 10, 25 | Not available |
| 2025/0115,654 | PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF | Nov 11, 22 | Apr 10, 25 | Not available |
| 2025/0115,672 | CANINE ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF | Jun 13, 24 | Apr 10, 25 | Not available |
| 2025/0108,020 | COMPOSITIONS AND COMPOUNDS CONTAINNG BETA-HYDROXYBUTYRATE AND ONE OR MORE AMINO ACIDS | Dec 11, 24 | Apr 03, 25 | Not available |
| 2025/0108,038 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | Sep 27, 24 | Apr 03, 25 | Supernus Pharmaceuticals, Inc. |
| 2025/0109,168 | POLYPEPTIDE AND USE THEREOF IN REGULATING BLOOD GLUCOSE LEVEL AND/OR REDUCING FAT | Sep 24, 24 | Apr 03, 25 | Not available |
| 2025/0109,191 | METHODS FOR ALTERING BODY COMPOSITION BY ADMINISTERING A GDF8 INHIBITOR AND AN ACTIVIN A INHIBITOR | Oct 09, 24 | Apr 03, 25 | Not available |
| 2025/0099,411 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | Apr 24, 24 | Mar 27, 25 | Institut Pasteur de Montevideo; Universidad de la República; |
| 2025/0099,452 | COMPOSITIONS COMPRISING MIXTURES OF COMPOUNDS AND USES THEREOF | Dec 10, 24 | Mar 27, 25 | Not available |
| 2025/0090,485 | COMPOSITIONS CONTAINING HMB AND KETONE BODIES AND METHODS FOR INCREASING LEAN-TO-FAT MASS RATIO | Nov 25, 24 | Mar 20, 25 | Not available |
| 2025/0092,041 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | Nov 22, 24 | Mar 20, 25 | Chugai Seiyaku Kabushiki Kaisha |
| 2025/0082,717 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | May 03, 24 | Mar 13, 25 | Not available |
| 2025/0084,142 | LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE | Sep 18, 24 | Mar 13, 25 | Not available |
| 2025/0084,144 | DUAL-TARGET FUSION PROTEINS COMPRISING FGF21 AND GLP-1, CONNECTED THROUGH A FC PORTION OF AN IMMUNOGLOBULIN | Aug 15, 24 | Mar 13, 25 | SUNSHINE LAKE PHARMA CO., LTD |
| 2025/0084,388 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF | Jun 20, 24 | Mar 13, 25 | Not available |
| 2025/0074,964 | STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS | Sep 05, 24 | Mar 06, 25 | Not available |
| 2025/0075,168 | METHOD FOR REGULATING BLOOD GLUCOSE, LOSING WEIGHT, AND REDUCING PRODUCTION OF ADVANCED GLYCATION END PRODUCTS BY USING SACCHAROMYCES CEREVISIAE TCI907 AND/OR METABOLITE THEREOF | Jan 25, 24 | Mar 06, 25 | Not available |